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Where does insulin resistance start? The liver
GIANLUCA PERSEGHIN, MD
THE CENTRAL ROLE OF THE
LIVER— Insulin resistance and the in-
sulinresistancesyndromerefertoaconstel-
lation of anthropometric and metabolic
features that may be summarized as over-
weight/obesity, glucose intolerance, dys-
lipidemia, and hypertension. These
anthropometric and metabolic abnor-
malities are associated with type 2 diabe-
tes, cardiovascular disease, polycystic
ovary syndrome, and nonalcoholic fatty
liver disease. The liver plays a central role
in the regulation of whole-body glucose,
fatty acid, and amino acid metabolism. It
is the main source of endogenous glucose
production, it is a major site of fatty acid
disposal (esteriﬁcation and oxidation)
and of amino acid metabolism, and it is
the primary site of insulin degradation.
Tissue-speciﬁc insulin receptor
knockout mice
Studies using tissue-speciﬁc insulin re-
ceptor knockout have demonstrated that
mice lacking the muscle insulin receptor
alone (MIRKO) are characterized by re-
duced insulin-stimulated muscle glucose
uptake,buttotal-bodyglucosehomeosta-
sis remained normal (1). Adipose tissue
insulin receptor knockout mice (FIRKO)
had impaired adipose tissue glucose up-
take but were protected against obesity,
glucose intolerance, and dyslipidemia
and manifested a prolonged lifespan (1).
In contrast, knockout of the insulin re-
ceptor in the liver resulted in both fasting
and postprandial hyperglycemia and the
subsequent development of peripheral
(muscle) insulin resistance. Collectively,
these observations support the view that
hepatic insulin resistance is the primary
event and leads to the subsequent devel-
opment of peripheral (muscle and adi-
pose) tissue insulin resistance.
The model of nonalcoholic fatty liver
disease
Nonalcoholic fatty liver disease (NAFLD)
is part of the broad spectrum of nonalco-
holic fatty liver diseases, which also in-
cludes steatosis. The distinction between
fatty liver and steatohepatitis only can be
made by examination of liver histology,
whichallowstheassessmentofinﬂamma-
tory inﬁltrate, cellular degeneration, and
necrosisandﬁbrosis,andcannotbemade
on the basis of clinical or laboratory pa-
rameters. Despite the weak correlation
betweenliverfunctiontestsandthesever-
ity of liver disease, epidemiological stud-
ies have shown that transaminases, and,
in particular, elevated alanine amino-
transferase (ALT), even if in the normal
range, predict new-onset type 2 diabetes
independent of classic risk factors, meta-
bolic syndrome, and C-reactive protein
(2). The authors postulated that elevated
intrahepatic fat (IHF) content played a
central role in liver damage and glucose
intolerance. Fatty liver is the most com-
mon hepatic disorder characterized by
triglyceride accumulation within hepato-
cytes. Although simple fatty liver is
thought to be a benign condition, it is
characterized by multiple metabolic ab-
normalities in organs and tissues that are
responsive to insulin. Impaired insulin-
mediated inhibition of hepatic glucose
production (3,4), reduced insulin-
stimulated glucose uptake in skeletal
muscle (3,5,6), and decreased inhibition
of lipolysis by insulin (3,6) has been doc-
umented in patients with fatty liver dis-
ease. Whether the accumulation of fat in
the liver is the primary event leading to
hepatic and subsequently peripheral
(muscle and adipose tissue) insulin resis-
tance is not clear because of the lack of
longitudinal data. In support of primacy
of the liver, treatment of type 2 diabetic
patients with a hypocaloric very-low-fat
diet resulted in an 81% reduction in IHF
content in association with reductions in
both basal and insulin-suppressed he-
patic glucose production and a decrease
in FPG concentration (7). However, there
was no signiﬁcant improvement in insu-
lin-stimulated peripheral glucose dis-
posal (7). Also, in insulin-treated type 2
diabetic patients, the IHF content was
closely correlated with the insulin dose
and the sensitivity of endogenous (he-
patic) glucose production to insulin and
best explained the interindividual varia-
tion in insulin requirements (8). More-
over, when the relationship between
peripheral glucose metabolism and fatty
liver were explored in healthy nondia-
betichumans,thecorrelationbetweenthe
IHF content and peripheral insulin resis-
tance was much stronger than the corre-
lation with intramyocellular lipid
content, visceral fat content, or subcuta-
neous fat content (9). Stefan et al. (10)
recently reported that in the model of the
metabolically ﬁt, but obese individuals,
preserved insulin sensitivity was more
strongly associated with lower IHF con-
tent than with other parameters of body
adiposity, including intramyocellular
lipid content, concluding that ectopic fat
in the liver may be more important than
visceral fat in the determination of such a
beneﬁcial phenotype in obesity. Similar
conclusionswerealsoreportedinindivid-
ualswithoverttype2diabetes(11).Inthe
samelineofevidence,weobservedthatin
obese adolescents with fatty liver, there
was a greater severity of whole-body in-
sulin resistance compared with that of
BMI-matched insulin-resistant obese ad-
olescents with normal IHF content (12).
Finally,thelackofadiposetissueinthe
congenital lipodystrophy is characterized
by extreme insulin resistance associated
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tervention with subcutaneous leptin ad-
ministration in these patients improved
whole-body insulin sensitivity mainly due
to the mobilization of the excessive fatty
liver content (13).
These ﬁndings in humans suggest
that IHF content has an important sys-
temic consequence to adversely affect in-
sulin sensitivity. The above-described
observations in humans are consistent
with studies in animal models. When an
isocaloric moderate-fat diet was given to
dogs, a modest degree of peripheral insu-
lin resistance was triggered; meanwhile, a
complete inability of insulin to suppress
hepatic glucose production during the
clamp developed (14). In rodents, in-
creasing or decreasing IHF content had
the opposite effect on muscle insulin sen-
sitivity, suggesting that fat accumulation
inthelivermaybetheprimaryeventlead-
ing to peripheral insulin resistance (15).
When liver-speciﬁc enhancement of fatty
acid oxidation was implemented in rats
fed a high-fat diet, insulin-stimulated pe-
ripheral glucose uptake was enhanced
even though intramyocellular lipid content
actually increased in some muscle types.
Morerecently,selectivehepaticoverexpres-
sion of glycerol-sn-3-phosphate acyltrans-
ferase 1 in rats caused hepatic steatosis
and hepatic insulin resistance in the ab-
senceofobesityand,surprisingly,triglyc-
erides accumulated in the gastrocnemius
muscle in concert with development of
insulinresistanceinthattissue(16).Ithas
beenproposedthatthelivermightrelease
a humoral factor that sensitizes skeletal
muscletoinsulin(17),andthissuggestive
hypothesis is supported by the observa-
tion that liver extracts enhanced glucose
uptake in the isolated rat hindquarter
(18). According to this scenario, periph-
eral insulin resistance may develop as the
resultofintrahepaticfataccumulation,re-
sulting in the lower release of these hu-
moral factors that impair insulin
sensitivity in peripheral (muscle) tissues.
Alternatively, it is possible that fatty liver
might interfere with insulin degradation
(19); the resultant hyperinsulinemia may
potentially be able to impair insulin ac-
tion in peripheral (muscle and adipose)
tissues, as shown in benign insulinoma-
induced hyperinsulinemia (20). This hy-
perinsulinemia-induced mechanism may
be justiﬁed also based on the ﬁnding of
the reverse experiment: when the pro-
longed infusion of octreotide was admin-
istered to extremely insulin-resistant
cirrhoticindividuals,thecorrectionofhy-
perinsulinemia was paralleled by the res-
torationofnormalinsulinsensitivity(21).
The liver in the phenotype of the
insulin resistance syndrome
Proinﬂammatory features. NAFLD is
considered the hepatic equivalent of the
metabolic syndrome (3,22). This is not
surprising since NAFLD is closely associ-
ated with obesity, diabetes, dyslipidemia,
and insulin resistance (the main features
of the metabolic syndrome). Recently, it
has been reported that excessive accumu-
lation of fat in the liver rather than in the
muscle is associated with features of the
metabolic syndrome (23). Liver fat was
shown to be ﬁvefold higher in individuals
with the metabolic syndrome than in
those without the metabolic syndrome,
and this ﬁnding was independent of obe-
sity (23). No differences in intramyocel-
lular lipid content was observed between
subjects with and without the metabolic
syndrome. Another feature common to
bothNAFLDandthemetabolicsyndrome
is the presence of a low-grade inﬂamma-
tory state in adipose tissue and in the
liver. The potential link between inﬂam-
mation and the metabolic syndrome may
well be the increased amount of circulat-
ing and intracellular fatty acids concen-
tration that are associated with an
increase in the intranuclear and total cel-
lularnuclearfactor(NF)-B(24).Ofnote,
liver biopsy of individuals with fatty inﬁl-
tration were characterized by increased
expression of genes involved in mono-
cyte/macrophagerecruitmentandinﬂam-
mation, and this was proportional to the
severity of IHF accumulation (25). An at-
tractive hypothesis to account, not only
for the metabolic but also for the proin-
ﬂammatory effects of fatty acids in the
liver, is that increased concentrations of
intracellular fatty acid metabolites (diac-
ylglycerol, fatty acyl CoAs, etc.) activate
IB kinase (IKK)- and NF-B (26).
Chronicinﬂammationoftheliversecond-
ary to triglyceride inﬁltration could
therebyincreasetheproductionoffactors
that cause systemic insulin resistance. Re-
sults in animal models also support this
hypothesis. Transgenic activation of the
inﬂammatory mediators IKK- and
NF-Bintheliverinducesystemicinsulin
resistance, increase circulating levels of
interleukin (IL)-6, and upregulate IL-6
target genes in peripheral tissues, includ-
ing muscle (27). Conversely, administra-
tionofantibodiestoneutralizecirculating
IL-6 normalized IL-6 target gene expres-
sion and corrected the insulin resistance.
Proatherosclerotic features. Subjects
with features of the metabolic syndrome
are at risk of developing cardiovascular
disease and coronary heart disease (28),
andrecentevidencesuggeststhatindivid-
uals with NAFLD also are at high risk for
coronary heart disease. In a prospective
study, the 14-year risk of mortality from
cardiovascular causes was doubled in pa-
tients with biopsy-proven NAFLD com-
paredwithareferencepopulation(29).In
theHoornStudy,elevatedALTatbaseline
increased the 10-year risk of coronary
heart disease events, even after adjust-
mentforthecomponentsofthemetabolic
syndrome (30). Cardiovascular risk fac-
tors tend to cluster in patients with
NAFLD, who exhibit more advanced ath-
erosclerosis than control subjects (31).
Recently, we reported that cardiac meta-
bolic remodeling in young men with fatty
liver is an early event and occurs before
the development of diastolic dysfunction
and is independent of known risk factors
for cardiovascular disease (age, obesity,
hypertension, diabetes, exercise habits)
(32). This ﬁnding was associated with al-
teration of surrogate markers of endothe-
lial dysfunction as previously detected
(33). Finally, it has been demonstrated
that 100% of mice with selective liver
knockout of the insulin receptor gene
(LIRKO)—a pure hepatic insulin resis-
tance—develop the metabolic syndrome
with severe dyslipidemia and atheroscle-
rosis within 12 weeks after being placed
on an atherogenic diet. None of the con-
trol mice developed the metabolic syn-
drome or atherosclerosis (34).
The model of liver cirrhosis
Patients with liver cirrhosis are character-
ized by impaired glucose metabolism
(35); 60–80% are glucose intolerant and
10–15% develop overt diabetes (36–38).
The development of diabetes in patients
with liver cirrhosis occurs relatively rap-
idly; over a period of 5 years, 15–20%
of cirrhotic patients develop frank hyper-
glycemia (39). Diabetes complicating
liver cirrhosis, known as hepatogenous
diabetes, and the common form of type 2
diabetes are the result of a marked reduc-
tion in insulin action and a -cell secre-
tory defect that is not able to compensate
for the severity of insulin resistance (40).
Peripheralinsulinresistanceplaysamajor
role in its pathogenesis (41,42). The pe-
ripheral insulin resistance in these pa-
tients has been assessed with positron
emissiontomographyoftheskeletalmus-
cle and has been shown to be associated
Perseghin
care.diabetesjournals.org DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 S165with both impaired glucose transport and
glycogen synthesis (43). The important
role of peripheral insulin resistance in the
glucose tolerance of cirrhosis is highlighted
by the observation that liver transplanta-
tion, when the dosage of immunosuppres-
sive agents is reduced and corticosteroids
withdrawn, is able to restore normal insu-
linsensitivitynotonlyintheliverbutalso
at the level of the skeletal muscle and ad-
ipose tissue (44) and normalizes glucose
tolerance in most patients with diabetes
(40).
CONCLUSIONS — In support of the
supremacy of the role of the liver in the
onset of insulin resistance and insulin re-
sistancesyndrome,westatethefollowing:
1) NAFLD is the hepatic equivalent of the
metabolic syndrome. 2) Even though
there are no longitudinal data showing
that the development of NAFLD is pri-
mary and precedes the onset of whole-
body insulin resistance, it is plausible,
based on animal studies, that the devel-
opment of peripheral insulin resistance
andproinﬂammatorystateissecondaryto
hepatic fat inﬁltration and hepatic insulin
resistance. 3) Models in which hepatic
dysfunction is known to be the primary
disturbance provide strong support that
insulinresistanceinperipheraltissuesde-
velops secondary to the liver disease; this
is manifested in humans in patients with
hepatic cirrhosis.
A ﬁnal consideration is that insulin
resistance is often deﬁned based on mea-
surements of glucose metabolism, but in-
sulin also regulates the anabolism and
storage of fat, protein synthesis, and non-
metabolicprocesssuchascellgrowthand
differentiation. In the insulin resistance
syndrome, it is important to emphasize
that not all insulin-dependent processes
andtissuesareequallyresistanttoinsulin.
Metabolic pathways at the liver site are a
good example of this behavior. Accili and
coworkers (45) proposed that, when in-
sulinsignalinginhepatocytesisimpaired,
the transcription factor forkhead box O1
(FoxO1) may play a pivotal role in sus-
taining this mixed state of resistance
versus sensitivity to insulin. This heter-
ogeneous phenotype (insulin resistance
with respect to glucose metabolism and
insulinsensitivitywithrespecttolipogen-
esis) seems to be a typical behavior of the
liverabletoexplainsimultaneouslyallthe
metabolic features (dysglycemia and dys-
lipidemia) of the insulin resistance
syndrome.
Acknowledgments— The writing of this ar-
ticle was supported by a grant from the Euro-
pean Federation for the Study of Diabetes and
by European Community’s Framework Pro-
gramme 6, Estrogen and Women Aging
(LSHM-CT-2005-518245).
No potential conﬂicts of interest relevant to
this article were reported.
References
1. Biddinger SB, Kahn CR. From mice to
men: insights into the insulin resistance
syndromes. Annu Rev Physiol 2006;68:
123–158
2. Sattar N, Scherbakova O, Ford I, O’Reilly
D St J, Stanley A, Forrest E, MacFarlane
PW, Packard CJ, Cobbe SM, Shepherd J.
Elevated alanine aminotransferase pre-
dicts new-onset type 2 diabetes indepen-
dently of classical risk factors, metabolic
syndrome, and C-reactive protein in the
West of Scotland Coronary Prevention
Study. Diabetes 2004;53:2855–2860
3. Marchesini G, Brizi M, Bianchi G, Tomas-
setti S, Bugianesi E, Lenzi M, McCullough
AJ, Natale S, Forlani G, Melchionda N.
Nonalcoholic fatty liver disease: a feature
of the metabolic syndrome. Diabetes
2001;50:1844–1850
4. Seppala-Lindroos A, Vehkavaara S, Hak-
kinen AM, Goto T, Westerbacka J, Sovi-
jarvi A, Halavaara J, Yki-Jarvinen H. Fat
accumulation in the liver is associated
withdefectsininsulinsuppressionofglu-
coseproductionandserumfreefattyacids
independent of obesity an normal men.
J Clin Endocrinol Metab 2002;87:3023–
3028
5. Bugianesi E, Gastaldelli A, Vanni E,
Gambino R, Cassader M, Baldi S, Ponti V,
Pagano G, Ferrannini E, Pizzetto M. Insu-
lin resistance in non-diabetic patients
withnon-alcoholicfattyliverdisease:sites
and mechanisms. Diabetologia 2005;48:
634–642
6. Pietilainen KH, Rissanen A, Kaprio J,
Makimattila S, Hakkinen A-M, Wester-
backa J, Sutinen J, Vehkavaara S, Yki-
JarvinenH.Acquiredobesityisassociated
with increased liver fat, intra-abdominal
fat, and insulin resistance in young adult
monozygotic twins. Am J Physiol 2005;
288:E768–E774
7. Petersen KF, Dufour S, Befroy D, Lehrke
M, Hendler RE, Shulman GI. Reversal of
nonalcoholichepaticsteatosis,hepaticin-
sulin resistance, and hyperglycemia by
moderate weight reduction in patients
with type 2 diabetes. Diabetes 2005;54:
603–608
8. Ryysy L, Ha ¨kkinen A-M, Goto T, Veh-
kavaara S, Westerbacka J, Halavaara J,
Yki-Ja ¨rvinen H. Hepatic fat content and
insulin action on free fatty acids and glu-
cose metabolism rather than insulin ab-
sorption are associated with insulin
requirements during insulin therapy in
type 2 diabetic patients. Diabetes 2000;
49:749–758
9. Hwang J-H, Stein DT, Barzilai N, Cui
M-H, Tonelli J, Kishore P, Hawkins M.
Increasedintrahepatictriglycerideisasso-
ciated with peripheral insulin resistance:
in vivo MR imaging and spectroscopy
studies. Am J Physiol Endocrinol Metab
2007;293:E1663–E1669
10. StefanN,KantartzisK,MachannJ,Schick
F, Thamer C, Rittig K, Balletshofer B,
Machicao F, Fritsche A, Haring H-U.
Identiﬁcation and characterization of
metabolically benign obesity in humans.
Arch Intern Med 2008;68:1609–1616
11. Gastaldelli A, Cusi K, Pettiti M, Hardies J,
Miyazaki Y, Berria R, Buzzigoli E, Sironi
AM, Cersosimo E, Ferrannini E, De
FRonzo RA. Relationship between hepat-
ic/visceralfatandhepaticinsulinresistance
in nondiabetic and type 2 diabetic subjects.
Gastroenterology 2007;133:496–506
12. Perseghin G, Bonfanti R, Magni S, Lat-
tuada G, De Cobelli F, Canu T, Esposito
A, Scifo P, Ntali G, Costantino F, Bosio
L,RagognaF,DelMaschioA,Chiumello
G, Luzi L. Insulin resistance and whole
body energy homeostasis in obese ado-
lescents with fatty liver disease. Am J
Physiol Endocrinol Metab 2006;291:
E697–E703
13. Petersen KF, Arioglu Oral E, Dufour S,
Befroy D, Ariyan C, Yu C, Cline GW,
DePaoli AM, Taylor SI, Gorden P, Shul-
man GI. Leptin reverses insulin resistance
and hepatic steatosis in patients with se-
vere lipodystrophy. J Clin Invest 2002;
109:1345–1350
14. Kim SP, Ellmerer M, Van Citters GW,
Bergman RN. Primacy of hepatic insulin
resistance in the development of the met-
abolic syndrome induced by an isocaloric
moderate-fat diet in the dog. Diabetes
2003;52:2453–2460
15. An J, Muoio DM, Shiota M, Fujimoto Y,
Cline GW, Shulman GI, Koves TR,
Stevens R, Millington D, Newgard CB.
Hepatic expression of malonyl-CoA de-
carboxylase reverses muscle, liver, and
whole animal insulin resistance. Nat Med
2004;10:268–274
16. Nagle CA, An J, Shiota M, Torres TP,
Cline GW, Liu Z-X, Wang S, Catlin RL,
Shulman GI, Newgard CB, Coleman RA.
Hepatic overexpression of glycerol-sn-3-
phosphate acyltransferase 1 in rats causes
insulin resistance. J Biol Chem 2007;282:
14807–14815
17. Lautt WW. The HISS story overview: a
novelhepaticneurohumoralregulationof
peripheral insulin sensitivity in health
and diabetes. Can J Physiol Pharmacol
1999;77:553–562
18. Petersen KF, Tygstrup N. A liver factor
increasing glucose uptake in rat hind-
quarters. J Hepatol 1994;20:461–465
19. Kotronen A, Vehkavaara S, Seppa ¨la ¨-Lin-
Where does insulin resistance start?
S166 DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 care.diabetesjournals.orgdroos A, Bergholm R, Yki-Jarvinen H. Ef-
fect of liver fat on insulin clearance. Am J
Physiol Endocrinol Metab 2007;293:
E1709–E1715
20. Battezzati A, Terruzzi I, Perseghin G, Bi-
anchi E, Di Carlo V, Pozza G, Luzi L.
Defective insulin action on protein and
glucose metabolism during chronic hy-
perinsulinemia in subjects with benign
insulinoma.Diabetes1995;44:837–844
21. Petrides AS, Stanley T, Matthews DE,
Vogt C, Bush AJ, Lambeth A. Insulin
resistance in cirrhosis: prolonged re-
ductionofhyperinsulinemianormalizes
insulin sensitivity. Hepatology 1998;
28:141–149
22. Marchesini G, Bugianesi E, Forlani G,
Cerrelli F, Lenzi M, Manini R, Natale S,
Vanni E, Villanova N, Melchionda N, Piz-
zetto M. Nonalcoholic fatty liver, steato-
hepatitis, and the metabolic syndrome.
Hepatology 2003;37:917–923
23. Kotronen A, Seppa ¨la ¨-Lindroos A, Berg-
holm R, Yki-Ja ¨rvinen H. Tissue speciﬁcity
of insulin resistance in humans: fat in the
liver rather than muscle is associated with
features of the metabolic syndrome. Dia-
betologia 2008;51:130–138
24. TripathyD,MohantyP,DhindsaS,SyedT,
Ghanim H, Aljada A, Dandona P. Elevation
offreefattyacidsinducesinﬂammationand
impairs vascular reactivity in healthy sub-
jects. Diabetes 2003;52:2882–2887
25. Westerbacka J, Kolak M, Kiviluoto T,
Arkkila P, Siren J, Hamsten A, Fisher RM,
Yki-Jarvinen H. Genes involved in fatty
acid partitioning and binding, lipolysis,
monocyte/macrophage recruitment, and
inﬂammation are overexpressed in the
human fatty liver of insulin-resistant sub-
jects. Diabetes 2007;56:2759–2765
26. Perseghin G, Petersen KF, Shulman GI.
Cellular mechanisms of insulin resis-
tance: potential links with inﬂammation.
Int J Obes 2003;27:S6–S11
27. Cai D, Yuan M, Frantz FD, Melendez PA,
Hansen L, Lee J, Shoelson SE. Local and
systemic insulin resistance resulting from
hepatic activation of IKK-beta and NF-
kappaB. Nat Med 2005;11:183–190
28. Dekker JM, Girman C, Rhodes T, Nijpels
G, Stehouwer CD, BouterLM, Heine RJ.
Metabolic syndrome and 10-year cardio-
vascular disease risk in the Hoorn Study.
Circulation 2005;12:666–673
29. Ekstedt M, Franzen LE, Mathiesen UL,
Thorelius L, Holmqvist M, Bodemar G,
Kechagias S. Long-term follow-up of pa-
tients with NAFLD and elevated liver en-
zymes. Hepatology 2006;44:865–873
30. Schindhelm RK, Dekker JM, Nijpels G,
BouterLM,StehouwerCD,HeineRJ,Dia-
mant M. Alanine aminotransferase pre-
dicts coronary heart disease events: a 10-
year follow-up of the Hoorn Study.
Atherosclerosis 2007;191:391–396
31. TargherG,BertoliniL,PadovaniR,Zenari
L,ZoppiniG,FralezzaG.Relationofnon-
alcoholic hepatic steatosis to early carotid
atherosclerosisinhealthymen:roleofvis-
ceral fat accumulation. Diabetes Care
2004;27:2498–2500
32. Perseghin G, Lattuada G, De Cobelli F,
Esposito A, Belloni E, Ntali G, Canu T,
RagognaF,ScifoP,DelMaschioA,LuziL.
Left ventricular energy metabolism is im-
paired and the intrapericardial and medi-
astinal fat is increased in young, non-
diabeticmenwithnewlyfoundfattyliver.
Hepatology 2008;47:51–58
33. Villanova N, Moscatello S, Ramilli S, Bu-
gianesi E, Magalotti D, Vanni E, Zoli M,
Marchesini G. Endothelial dysfunction
and cardiovascular risk proﬁle in nonal-
coholic fatty liver disease. Hepatology
2005;42:473–480
34. Biddinger SB, Hernandez-Ono A, Rask-
Madsen A, Haas JT, Aleman J, Suzuki R,
Scapa EF, Agarwal C, Carey MC, Stepha-
nopoulos G, Cohen DE, King GL, Gins-
berg HN, Kahn CR. Hepatic insulin
resistance is sufﬁcient to produce dyslip-
idemia and susceptibility to atherosclero-
sis. Cell Metab 2008;7:125–134
35. Naunyn B. Glykosurie und Diabetes durch
experimentelle Insulte und Krankheiten
der Leber. In Handbuch Spezielle Pathologie
Therapie Band 7, 1. Holder A, Ed. Wien,
Austria, 1898, p. 38–49
36. Megyesi C, Samols E, Marks V. Glucose
tolerance and diabetes in chronic liver
disease. Lancet 1967;2:1051–1056
37. Conn HO, Schreiber W, Elkington SG,
Johnson TR. Cirrhosis and diabetes: in-
creased incidence of diabetes in patients
with Laennec’s cirrhosis. Am J Dig Dis
1969;14:837–852
38. Conn HO, Schreiber W, Elkington SG.
Cirrhosis and diabetes: association of im-
paired glucose tolerance with portal-sys-
temic shunting in Laennec’s cirrhosis.
Am J Dig Dis 1971;16:227–239
39. Gentile S,Loguercio C, Marmo R, Carbone
L, Del Vecchio-Blanco C. Incidence of al-
teredglucosetoleranceinlivercirrhosis.Di-
abetes Res Clin Pract 1993;22:37–44
40. PerseghinG,MazzaferroV,PiceniSereniL,
Regalia E, Benedini S, Bazzigaluppi E, Pul-
virenti A, Antonio Silva Lea ˜o A, Calori G,
RomitoR,BarattiD,LuziL.Contributionof
reduced insulin sensitivity and secretion to
the pathogenesis of hepatogenous diabetes:
effect of liver transplantation. Hepatology
2000;31:694–703
41. Petrides AS, De Fronzo RA. Glucose me-
tabolism in cirrhosis: a review with some
perspectivesforthefuture.DiabeteMetab
Rev 1989;5:691–709
42. Petrides AS, Groop LC, Riely CA, De
Fronzo RA. Effect of physiologic hyperin-
sulinemia on glucose and lipid metabo-
lism in cirrhosis. J Clin Invest 1991;88:
561–570
43. SelbergO,BurchertW,vdHoffJ,MeyerGJ,
HundeshagenH,RadochE,BalksH-J,Mul-
ler MJ. Insulin resistance in liver cirrhosis:
positron-emission tomography scan analy-
sis of skeletal muscle glucose metabolism.
J Clin Invest 1993;91:1897–1902
44. Perseghin G, Regalia E, Battezzati A, Ver-
gani S, Pulvirenti A, Terruzzi I, Baratti D,
Bozzetti F, Mazzaferro V, Luzi L. Regula-
tion of glucose homeostasis in humans
with a denervated liver. J Clin Invest
1997;100:931–941
45. Matsumoto M, Han S, Kitamura T, Accili
D.DualroleoftranscriptionfactorFoxO1
in controlling hepatic insulin sensitivity
and lipid metabolism. J Clin Invest 2006;
116:2464–2472
Perseghin
care.diabetesjournals.org DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 S167